


World Journal of *Radiology*

World J Radiol 2020 July 28; 12(7): 130-141



MINIREVIEWS

- 130 Lung cancer screening, what has changed after the latest evidence?

Trujillo-Reyes JC, Seijo L, Martínez-Tellez E, Couñago F

CASE REPORT

- 137 Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report

Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A

ABOUT COVER

Editorial board member of *World Journal of Radiology*, Dr. Gao is a distinguished Professor in Shijiazhuang First Hospital, Hebei Medical University. Currently, he is a special expert hired by the Hebei Provincial Government, a distinguished expert of "100 overseas talents plan" of Hebei Province, and an expert enjoying special allowance of Hebei Provincial Government. His ongoing research interests are mechanisms and endovascular treatment of cerebral aneurysms, intracranial atherosclerotic diseases, aortic aneurysms, cerebrovascular diseases, arterial stenosis, computational fluid dynamics of vascular diseases, neurointerventional radiology, animal experiments for vascular diseases, and animal models of all sorts of diseases. Dr. Gao has published over 120 SCI papers and serves as an expert reviewer for over 120 English journals including over 60 journals indexed by Web of Science.

AIMS AND SCOPE

The primary aim of *World Journal of Radiology* (*WJR*, *World J Radiol*) is to provide scholars and readers from various fields of radiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJR mainly publishes articles reporting research results and findings obtained in the field of radiology and covering a wide range of topics including state of the art information on cardiopulmonary imaging, gastrointestinal imaging, genitourinary imaging, musculoskeletal imaging, neuroradiology/head and neck imaging, nuclear medicine and molecular imaging, pediatric imaging, vascular and interventional radiology, and women's imaging.

INDEXING/ABSTRACTING

The *WJR* is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Electronic Editor: Ji-Hong Liu, Production Department Director: Yun-Xiaojuan Wu, Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Radiology

ISSN

ISSN 1949-8470 (online)

LAUNCH DATE

January 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Venkatesh Mani

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1949-8470/editorialboard.htm>

PUBLICATION DATE

July 28, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Lung cancer screening, what has changed after the latest evidence?

Juan Carlos Trujillo-Reyes, Luis Seijo, Elisabeth Martínez-Tellez, Felipe Couñago

ORCID number: Juan Carlos Trujillo-Reyes 0000-0002-3370-0869; Luis Seijo 0000-0001-9344-728X; Elisabeth Martínez-Tellez 0000-0002-5144-2963; Felipe Couñago 0000-0001-7233-0234.

Author contributions: Trujillo-Reyes JC was involved in the study conceptualization, investigation, data visualization and writing of the original draft; Seijo L performed formal analysis, review and editing of the manuscript; Martínez-Tellez E was involved in the investigation, data visualization and review and editing of the manuscript; Couñago F participated in the investigation, data validation and writing, review and editing of the manuscript; All authors have read and approved the final manuscript.

Conflict-of-interest statement: Dr. Seijo reports personal fees from Sabartech, personal fees from Esteve, personal fees from Chiesi, personal fees from Astra Zeneca, grants from Menarini, and speaking fees from Roche, outside the submitted work. Rest of authors declare no conflict of interests for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution

Juan Carlos Trujillo-Reyes, Elisabeth Martínez-Tellez, Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona 08029, Spain

Juan Carlos Trujillo-Reyes, Elisabeth Martínez-Tellez, Department of Surgery, Universitat Autònoma de Barcelona, Barcelona 08029, Spain

Luis Seijo, Department of Pneumology, Clínica Universitaria de Navarra, Madrid 28029, Spain

Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain

Felipe Couñago, Universidad Europea de Madrid, Madrid 28223, Spain

Felipe Couñago, Department of Radiation Oncology, Hospital La Luz, Madrid 28003, Spain

Corresponding author: Juan Carlos Trujillo-Reyes, MD, Adjunct Professor, Surgical Oncologist, Department of Thoracic Surgery, Hospital Universitari de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona 08029, Spain. jtrujillo@santpau.cat

Abstract

Lung cancer (LC) is still one of the most frequent cancers with a high related mortality. Their prognosis is directly proportional to the stage at the time of diagnosis. Seventy percent are currently diagnosed in advanced or locally advanced stage (higher than stage III), making a cure unlikely for the majority of patients. Developments in LC treatment are significant however they do not seem to be enough to reverse the current situation, at least, in a short period of time. Despite recent advances in treatment, primary prevention and early diagnosis appear to be the key to reduce the incidence and mortality of this disease. Many countries have developed LC screening programs based on the results of clinical trials published in recent years. The aim of this paper is to review the latest results of the Netherlands Leuven Longkanker Screenings Onderzoek and compare them with the findings of the National Lung Screening Trial. We address the question whether it is necessary to continue discussing the evidence regarding LC screening. In both trials, there is a clear impact on LC mortality but, with a modest reduction in overall mortality. Undoubtedly, the benefit of screening can be expected to grow as low-dose computed tomography scans are performed over longer periods of time.

Key words: Lung cancer; Epidemiology; Lung cancer screening; Low dose chest computed tomography scan; Primary prevention; Molecular biomarkers

NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Received: March 30, 2020

Peer-review started: March 30, 2020

First decision: April 26, 2020

Revised: June 11, 2020

Accepted: July 1, 2020

Article in press: July 1, 2020

Published online: July 28, 2020

P-Reviewer: Neninger E, Sung WW, Zhou C

S-Editor: Liu M

L-Editor: A

E-Editor: Liu JH



©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In recent years, many publications have focused on primary prevention and Lung cancer (LC) screening. Currently, most scientific societies recommend some form of LC screening. However, implementation around the world has been slow, at least in part because of a continued controversy regarding some aspects of LC screening. The aim of this article is to analyze the recently published results of the NEDerlands Leuven Longkanker Screenings Onderzoek study and compare them to those of the American National Lung Screening Trial (NLST). There is a clear impact on LC mortality in both trials, but only the NLST revealed a reduction in overall mortality (7%).

Citation: Trujillo-Reyes JC, Seijo L, Martínez-Tellez E, Couñago F. Lung cancer screening, what has changed after the latest evidence? *World J Radiol* 2020; 12(7): 130-136

URL: <https://www.wjgnet.com/1949-8470/full/v12/i7/130.htm>

DOI: <https://dx.doi.org/10.4329/wjr.v12.i7.130>

INTRODUCTION

Lung cancer (LC) is the most lethal of all cancers. It is the leading cause of death from cancer worldwide and, year after year, the number of new LC cases grows^[1].

One of the most important prognostic factors is the stage at the time of diagnosis. Most patients are asymptomatic until they develop an advanced stage making an early diagnosis challenging^[2].

Despite important advance in oncological treatments, the prevalence and persistently elevated mortality associated with lung cancer demand a paradigm shift. Primary prevention initiatives must continue, but for many current and former smokers early recognition of pulmonary nodules must be pursued. Many countries have developed laws related to primary prevention that have proven insufficient to stem the tide of lung cancer. The combination of primary prevention and LC screening could help us fight the disease before it is too late.

LC screening has become a reality in the United States following completion of the National Lung Screening Trial (NLST)^[3]. The cultural gap existing between the United States and Europe and the difference between both health systems created some skepticism in the European community regarding the potential benefit of lung cancer screening programs in our continent. Results of the NEDerlands Leuven Longkanker Screenings Onderzoek (NELSON)^[4] study may assuage those concerns and provide a much needed impulse for efforts regarding the implementation of LC screening in Europe. Both trials investigated the role of low dose CT as the screening tool of choice^[5-8].

LUNG CANCER EPIDEMIOLOGY

The figures show how the global number of LC cases is increasing demonstrating that LC is the leading cause of cancer-related mortality worldwide. In 2015^[9], approximately 1.6 million new LC cases were diagnosed worldwide and, according to the World Health Organization, more than 2 million new cases were diagnosed in 2019 alone, and LC was responsible for the cancer 1.76 million deaths.

That notwithstanding, LC death rates declined 48% from 1990 to 2016 among men and 23% from 2002 to 2016 among women. The American Association for Cancer Research published in 2018 that lung cancer mortality rates among women are projected to increase by about 43 percent between 2015 to 2030.

This high mortality is related to the fact that 70% of cases are diagnosed in an advanced stage (stage III or IV disease)^[10] being the 5 year-survival a 16% for stage III and 4% for stage IV^[11].

Risk factors

Smoking continues being as the major etiological factor^[11], although occupational exposure to carcinogens such as asbestos and radon^[12,13], family history of LC^[14], genetic predisposition and other concomitant diseases may also play a role.

Tobacco use: It is the major etiological factor. We can prevent almost 200 million people from dying before 2050 halving tobacco consumption^[11], but smoking in many countries continues to increase. In Spain, for example, the number of smokers is the same in 2017 as in 1997 despite implementation of two anti-smoking laws is even greater among the youth. Unfortunately, it is not an isolated example. It is crucial to prevent smoking in adolescence because, the patients who started smoking within this age group, have four or five-fold increased risk of developing a LC^[15]. It is well known that passive smokers have a higher risk for LC when compared to nonsmokers. However, the association is too weak to be considered in a LC screening program^[16].

Occupational exposure: The association between LC and approximately 150 carcinogens is well known being asbestos, crystalline silica or radon^[17] a few examples. It is important to note that the combination of smoking and to be exposed to these carcinogens further increases the risk of developing LC. Air pollution may also play an important role in the development of LC in urban populations.

Pre-existing lung illnesses: (1) Chronic obstructive pulmonary disease (COPD), Emphysema, Bronchitis: COPD and emphysema are associated with an increased LC risk^[18-20]. This association may be caused by tobacco-use, however, this association is evidence in never-smokers too^[21,22]; and (2) Idiopathic pulmonary fibrosis: patients who develop interstitial fibrosis also have a higher risk to develop a LC^[23,24].

Genetic predisposition: A systematic review of the literature performed by Matakidou *et al*^[25] showed an increased risk of LC in patients with a first-degree relative with LC. A genetic locus that may be associated with a greatest risk of developing LC has been described^[26].

Identifying the presence of these risk factors could be crucial to define the population at risk and inform LC screening inclusion criteria.

LUNG CANCER SCREENING

The main objective of LC screening is to detect the greatest number of people in early stage when symptoms have not yet appeared and treatment with curative intent may be possible^[16]. It is important to consider that a LC screening program must take into account quality of life and life expectancy. Key elements of a successful screening program are defined in [Table 1](#).

In lung cancer screening, several questions must be addressed before implementation, but these are not easy questions to answer: What population should be screened? Is it safe and economically viable? What is the age of the population to be screened? What is the periodicity of the screening? What is the best screening tool?

In recent years several publications have attempted to address at least some of these concerns, and to provide the needed evidence to demonstrate the feasibility and efficacy of a LC screening program. Most of them used low-dose computed tomography (LDCT) as the main screening tool, however, only two randomized trials have been published using the LDCT test, NLST and recently published, NELSON trial.

NLST AND NELSON STUDIES

NLST, the North American evidence

The NLST was the first large prospective randomized trial investigating the benefit of LC screening. The aim of the NLST was to determine whether screening with LDCT could reduce mortality from LC and more than 50000 individuals at risk for LC were randomized to undergo three rounds of screening with LDCT or chest radiography. Inclusion criteria were restrictive including patients between 55 and 74 years old with a high smoking habit (≥ 30 pack/year).

The results of the NLST showed a reduction of more than 20% in LC mortality and 40% of LC detected were in early stage of the disease. False positive results were common demonstrating a Positive Predictive Value lower than 4% for LDCT. Part of the success was the high adherence from the study participants^[3].

Overdiagnosis was a major source of controversy surrounding the NLST, although a recent publication with long term follow up suggests that true overdiagnosis is approximately 3%.

Table 1 Quality criteria of a screening program

Quality criteria of a screening program ^[16]	
False-positive	Should be low
Cost	Inexpensive
True negative	Should not be hurt
Screening test should	Improve outcome; Be scientifically validated; Be low risk; Be reproducible; Be accessible; Be cost effective

NELSON, the European evidence

The NELSON trial is the largest randomized trial of LC screening, which the European health systems needed to adapt to our idiosyncrasies and population. Although, the sample size was smaller (less than 16000 participants) than the NLST's, the results confirm the reduction in lung cancer mortality^[4]. Inclusion criteria and intervals were flexible reducing the rate of false positives (positive predictive value 43.5%).

The impact of both trials highlights the reduction in LC mortality with no differences in overall survival compared to the control group. Table 2 shows details of both trials.

HOW TO IMPROVE LC SCREENING?

We are aware that LDCT screening requires compromises, and no screening program is ideal. Improvement in selection criteria and nodule management may come from molecular biomarkers^[27] and multiple potential candidates have been identified and studied in the context of LC screening^[28,29]. Autoantibodies, complement fragments, miRNAs, circulating tumour DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures are all promising molecular candidates. Seijo *et al*^[31] defined the two clinical needs of biomarkers; the selection of individuals undergoing screening and the characterization of indeterminate nodules^[27].

The strategy has to be focused on the addition of molecular biomarkers to current screening practices.

CONCLUSION

LC remains a health crisis worldwide with an increasing financial impact^[30]. It is now apparent that a combination of primary prevention and LC screening may be the key to reducing the incidence of this disease and its attendant mortality. The NLST^[3] has paved the way for LC screening in the United States, where it is now standard of care for those meeting the study's inclusion criteria. In Europe, a lack of evidence has been alluded to in order to delay implementation of screening. However, results of the NELSON study are now available and published confirming the benefit of LC screening for individuals at risk^[4].

In our opinion, both the NELSON and the NLST have provided sufficient scientific evidence to warrant widespread screening. Of course, both randomized trials can be criticized and we can continue discussing advantages and disadvantages of LC screening but, in our opinion, they confirm that LC screening is feasible and has a clear benefit on the population.

There is a clear impact on LC mortality but, in both trials, with a modest reduction in over all mortality. Undoubtedly, the benefit of screening can be expected to grow as LDCTs are performed over longer periods of time^[31].

LDCT is currently the test of choice. Addition of molecular biomarkers may offer a more selective approach in the future.

Table 2 Comparison between nlst and nelson

	NLST	NELSON
Age	55-74	50-74
Smoking habit	≥ 30 pack/year; ≥ 15 years since quitting	≥ 15 pack/year; ≥ 10 years since quitting
CT scan	Diameter-based	Volume-based
Sample size	53454	15822
Number of rounds	3	4
Intervals	1 yr intervals	0, 1, 2 and 2.5 yr
Adherence	95% LDCT group	87.6%
Number of cancers	1060 (645/100000 person/year)	5.58/1000 person/year
% early stage cancers	40% stage IA	50% stage IA
Positive test	24%	2.1%
PPV	3.8%	43.5%
Reduction in lung cancer mortality	20%	Higher than 20%
Population	North America	Europe

NLST: National Lung Screening Trial; NELSON: Nederlands Leuvens Longkanker Screenings Onderzoek; CT: Computed tomography; LDCT: Low-dose computed tomography; PPV: Positive predictive value.

ACKNOWLEDGEMENTS

We would like to express our gratitude to Jose Antonio Trujillo-Reyes for his contribution and to the rest of Thoracic Surgery, Radiotherapy and Pulmonology for allowing us to continue enjoying with our job.

REFERENCES

- 1 **Thun MJ**, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. *J Natl Cancer Inst* 2006; **98**: 691-699 [PMID: [16705123](#) DOI: [10.1093/jnci/djj187](#)]
- 2 **Tylski E**, Goyal M. Low Dose CT for Lung Cancer Screening: The Background, the Guidelines, and a Tailored Approach to Patient Care. *Mo Med* 2019; **116**: 414-419 [PMID: [31645796](#)]
- 3 **National Lung Screening Trial Research Team**. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**: 395-409 [PMID: [21714641](#) DOI: [10.1056/NEJMoa1102873](#)]
- 4 **de Koning HJ**, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoessein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *N Engl J Med* 2020; **382**: 503-513 [PMID: [31995683](#) DOI: [10.1056/NEJMoa1911793](#)]
- 5 **Saghir Z**, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, Døssing M, Hansen H, Kofoed KF, Larsen KR, Mortensen J, Rasmussen JF, Seersholm N, Skov BG, Thorsen H, Tonnesen P, Pedersen JH. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* 2012; **67**: 296-301 [PMID: [22286927](#) DOI: [10.1136/thoraxjnl-2011-200736](#)]
- 6 **Pastorino U**, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev* 2012; **21**: 308-315 [PMID: [22465911](#) DOI: [10.1097/CEJ.0b013e328351e1b6](#)]
- 7 **Infante M**, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. *Am J Respir Crit Care Med* 2015; **191**: 1166-1175 [PMID: [25760561](#) DOI: [10.1164/rccm.201408-1475OC](#)]
- 8 **Field JK**, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, Eisen T, Gosney J, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McDonald FE, Nair A, Page RD, Parmar MK, Rastl DM, Rintoul RC, Screaton NJ, Wald NJ, Weller D, Williamson PR, Yadegarfar G, Hansell DM. UK

- Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* 2016; **71**: 161-170 [PMID: [26645413](#) DOI: [10.1136/thoraxjnl-2015-207140](#)]
- 9 **Malvezzi M**, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? *Ann Oncol* 2015; **26**: 779-786 [PMID: [25623049](#) DOI: [10.1093/annonc/mdv001](#)]
- 10 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: [29313949](#) DOI: [10.3322/caac.21442](#)]
- 11 **Gouvêas C**, De Mello RA, Oliveira D, Castro-Lopes JM, Castelo-Branco P, Dos Santos RS, Hespanhol V, Pozza DH. Lung cancer: a brief review of epidemiology and screening. *Future Oncol* 2018; **14**: 567-575 [PMID: [29417838](#) DOI: [10.2217/fon-2017-0486](#)]
- 12 **Lee HA**, Lee WK, Lim D, Park SH, Baik SJ, Kong KA, Jung-Choi K, Park H. Risks of Lung Cancer due to Radon Exposure among the Regions of Korea. *J Korean Med Sci* 2015; **30**: 542-548 [PMID: [25931783](#) DOI: [10.3346/jkms.2015.30.5.542](#)]
- 13 **Selikoff IJ**, Churg J, Hammond EC. Asbestos exposure and neoplasia. *JAMA* 1964; **188**: 22-26 [PMID: [14107207](#) DOI: [10.1001/jama.1964.03060270028006](#)]
- 14 **Jonsson S**, Thorsteinsdottir U, Gudbjartsson DF, Jonsson HH, Kristjansson K, Arnason S, Gudnason V, Isaksson HJ, Hallgrímsson J, Gulcher JR, Amundadottir LT, Kong A, Stefánsson K. Familial risk of lung carcinoma in the Icelandic population. *JAMA* 2004; **292**: 2977-2983 [PMID: [15613665](#) DOI: [10.1001/jama.292.24.3026](#)]
- 15 **Minami H**, Yoshimura M, Matsuoka H, Toshihiko S, Tsubota N. Lung cancer treated surgically in patients <50 years of age. *Chest* 2001; **120**: 32-36 [PMID: [11451812](#) DOI: [10.1378/chest.120.1.32](#)]
- 16 **Wood DE**, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018; **16**: 412-441 [PMID: [29632061](#) DOI: [10.6004/jncn.2018.0020](#)]
- 17 **Lorenzo-González M**, Ruano-Ravina A, Torres-Durán M, Provencio-Pulla M, Kelsey K, Parente-Lamelas I, Vidal-García I, Leiro-Fernández V, Martínez C, Hernández J, Castro-Añón O, García-García S, Sales-Fidalgo P, Abal-Arca J, Montero-Martínez C, Pérez-Ríos M, Fernández-Villar A, Barros-Dios JM. Lung cancer risk and do-it-yourself activities. A neglected risk factor for lung cancer. *Environ Res* 2019; **179**: 108812 [PMID: [31698297](#) DOI: [10.1016/j.envres.2019.108812](#)]
- 18 **Houghton AM**, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. *Nat Med* 2008; **14**: 1023-1024 [PMID: [18841139](#) DOI: [10.1038/nm1008-1023](#)]
- 19 **Mayne ST**, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. *Am J Epidemiol* 1999; **149**: 13-20 [PMID: [9883789](#) DOI: [10.1093/oxfordjournals.aje.a009722](#)]
- 20 **Denholm R**, Schütz J, Straif K, Stücker I, Jöckel KH, Brenner DR, De Matteis S, Boffetta P, Guida F, Bröske I, Wichmann HE, Landi MT, Caporaso N, Siemiatycki J, Ahrens W, Pohlabeln H, Zaridze D, Field JK, McLaughlin J, Demers P, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Dumitru RS, Bencko V, Foretova L, Janout V, Kendzia B, Peters S, Behrens T, Vermeulen R, Brüning T, Kromhout H, C Olsson A. Is previous respiratory disease a risk factor for lung cancer? *Am J Respir Crit Care Med* 2014; **190**: 549-559 [PMID: [25054566](#) DOI: [10.1164/rccm.201402-0338OC](#)]
- 21 **Yang P**, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med* 2008; **168**: 1097-1103 [PMID: [18504338](#) DOI: [10.1001/archinte.168.10.1097](#)]
- 22 **Koshiol J**, Rotunno M, Consonni D, Pesatori AC, De Matteis S, Goldstein AM, Chaturvedi AK, Wacholder S, Landi MT, Lubin JH, Caporaso NE. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. *PLoS One* 2009; **4**: e7380 [PMID: [19812684](#) DOI: [10.1371/journal.pone.0007380](#)]
- 23 **Hughes JM**, Weill H. Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. *Br J Ind Med* 1991; **48**: 229-233 [PMID: [2025587](#) DOI: [10.1136/oem.48.4.229](#)]
- 24 **Khan KA**, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. *Lung* 2015; **193**: 71-77 [PMID: [25381634](#) DOI: [10.1007/s00408-014-9664-8](#)]
- 25 **Matakidou A**, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. *Br J Cancer* 2005; **93**: 825-833 [PMID: [16160696](#) DOI: [10.1038/sj.bjc.6602769](#)]
- 26 **Bailey-Wilson JE**, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, Klein C, Gazdar A, Rothschild H, Mandal D, Coons T, Slusser J, Lee J, Gaba C, Kupert E, Perez A, Zhou X, Zeng D, Liu Q, Zhang Q, Seminara D, Minna J, Anderson MW. A major lung cancer susceptibility locus maps to chromosome 6q23-25. *Am J Hum Genet* 2004; **75**: 460-474 [PMID: [15272417](#) DOI: [10.1086/423857](#)]
- 27 **Seijo LM**, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. *J Thorac Oncol* 2019; **14**: 343-357 [PMID: [30529598](#) DOI: [10.1016/j.jtho.2018.11.023](#)]
- 28 **Mazzone PJ**, Wang XF, Lim S, Jett J, Choi H, Zhang Q, Beukemann M, Seeley M, Martino R, Rhodes P. Progress in the development of volatile exhaled breath signatures of lung cancer. *Ann Am Thorac Soc* 2015; **12**: 752-757 [PMID: [25965541](#) DOI: [10.1513/AnnalsATS.201411-540OC](#)]
- 29 **Nakhleh MK**, Amal H, Jerjes R, Broza YY, Aboud M, Gharra A, Iygi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkiewicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban

- A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. *ACS Nano* 2017; **11**: 112-125 [PMID: [28000444](#) DOI: [10.1021/acsnano.6b04930](#)]
- 30 **Elias F**, Bou-Orm IR, Adib SM, Gebran S, Gebran A, Ammar W. Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016). *J Glob Oncol* 2018; **4**: 1-7 [PMID: [30241263](#) DOI: [10.1200/JGO.17.00179](#)]
- 31 **Seijo LM**, Trujillo JC, Zulueta JJ. Screening in Lung Cancer: The Latest Evidence. *Arch Bronconeumol* 2020; **56**: 7-8 [PMID: [31204006](#) DOI: [10.1016/j.arbres.2019.04.019](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

